Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization. The primary goal of de-escalation is to investigate whether using an intermittent regime results in a similar OS to continuous treatment.

NCT Number	NCT05974774
Lead Sponsor	European Organisation for Research and Treatment of Cancer - EORTC Collaborators: Cancer Trials Ireland, UNICANCER, Spanish Oncology Genito-Urinary Group
Conditions	Prostate Cancer
Enrollment	1,600 participants
Start Date	2025-05-23
Primary Completion	2035-05-23 (estimated)
Study Completion	2039-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-19